CoChat

The amyloid hypothesis of Alzheimer's disease at 25 years

Open access
Selkoe, Dennis J, Hardy, John · 2016 · EMBO Molecular Medicine

The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.

Abstract

Despite continuing debate about the amyloid β-protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease (AD). Confirmation that presenilin is the catalytic site of γ-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ. Duplication of the wild-type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain. Soluble oligomers of Aβ42 isolated from AD patients' brains can decrease synapse number, inhibit long-term potentiation, and enhance long-term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory. The human oligomers also induce hyperphosphorylation of tau at AD-relevant epitopes and cause neuritic dystrophy in cultured neurons. Crossing human APP with human tau transgenic mice enhances tau-positive neurotoxicity. In humans, new studies show that low cerebrospinal fluid (CSF) Aβ42 and amyloid-PET positivity precede other AD manifestations by many years. Most importantly, recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201606210

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The sequence of major pathogenic events leading to AD proposed by the amyloid cascade hypothesis The curved blue arrow indicates that Aβ oligomers may directly injure the synapses and neurites of brain neurons, in addition to activating microglia and astrocytes.
Figure 1 The sequence of major pathogenic events leading to AD proposed by the amyloid cascade hypothesis The curved blue arrow indicates that Aβ oligomers may directly injure the synapses and neurites of brain neurons, in addition to activating microglia and astrocytes.CC BY · PubMed Central
Figure 2 Progressive cleavages of the APP transmembrane domain by the Presenilin/γ‐secretase complex
Figure 2 Progressive cleavages of the APP transmembrane domain by the Presenilin/γ‐secretase complexCC BY · PubMed Central
Figure 3 A hypothetical temporal model integrating Alzheimer's disease biomarkers The threshold for the first detection of biomarkers associated with pathophysiological changes is denoted by the black horizontal line. The gray area denotes the zone in which abnormal pathophysiological changes lie below this biomarker detection threshold. In this model, the occurrence of tau pathology can precede Aβ deposition in time, but only early on at a sub‐threshold biomarker detection level. Aβ deposition occurs independently and rises above the biomarker detection threshold (purple and red arrows). This induces acceleration of tauopathy, and CSF tau then rises above the detection threshold (light blue arrow). Later still, changes in FDG PET and MRI (dark blue arrow) rise above the detection threshold. Finally, cognitive impairment becomes evident (green arrow), with a wide range of cognitive responses that depend on the individual's risk profile (light green‐filled area). Note that while CSF Aβ42 alteration is plotted as a biomarker (purple), this represents a decrease in CSF Aβ42 levels and is a surrogate for an increase in parenchymal Aβ42 and changes in other Aβ peptides in the brain tissue. Aβ, amyloid β‐protein; FDG, fluorodeoxyglucose; MCI, mild cognitive impairment. (Adapted from Fig 6 of Jack et al, 2013.)
Figure 3 A hypothetical temporal model integrating Alzheimer's disease biomarkers The threshold for the first detection of biomarkers associated with pathophysiological changes is denoted by the black horizontal line. The gray area denotes the zone in which abnormal pathophysiological changes lie below this biomarker detection threshold. In this model, the occurrence of tau pathology can precede Aβ deposition in time, but only early on at a sub‐threshold biomarker detection level. Aβ deposition occurs independently and rises above the biomarker detection threshold (purple and red arrows). This induces acceleration of tauopathy, and CSF tau then rises above the detection threshold (light blue arrow). Later still, changes in FDG PET and MRI (dark blue arrow) rise above the detection threshold. Finally, cognitive impairment becomes evident (green arrow), with a wide range of cognitive responses that depend on the individual's risk profile (light green‐filled area). Note that while CSF Aβ42 alteration is plotted as a biomarker (purple), this represents a decrease in CSF Aβ42 levels and is a surrogate for an increase in parenchymal Aβ42 and changes in other Aβ peptides in the brain tissue. Aβ, amyloid β‐protein; FDG, fluorodeoxyglucose; MCI, mild cognitive impairment. (Adapted from Fig 6 of Jack et al, 2013.)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

26 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 136 references

Research works printed but not linked: 3

  1. Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, Clayton D, Mortensen D, Ho C, Paul R (2014) paper presented at the Alzheimer's Association International Conference (AAIC), Copenhagen, Denmark, 16 July 2014
  2. Mann DMA, Yuonis N, Jones D, Stoddart DW (1992) The time course of pathological events in Down's Syndrome with particular reference to the involvement of microglial cells and deposits of b/A4. Neurodegeneration 1: 201–215
  3. Sevigny J, Chiao P, Williams L, Miao X, O'Gorman J (2015) Randomized, double‐blind Phase 1B study of BIIB037, an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease. Neurogener Dis 15(Suppl 1): 311

Cited by

See all 6,164

Metadata

Authors
Selkoe, D. J., & Hardy, J.
Affiliations
  • Brigham and Women's Hospital (US)
  • UCL Queen Square Institute of Neurology (GB)
Corresponding author
Hardy, John
Venue
EMBO Molecular Medicine
Published
2016-03-29
Volume
8
Issue
6
Pages
595-608
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2329336071
Cited by
6,164
References
137
Citations by year
2026: 553 · 2025: 637 · 2024: 656 · 2023: 658 · 2022: 679 · 2021: 734 · 2020: 728 · 2019: 533 · 2018: 500 · 2017: 388 · 2016: 92
FWCI
59.19
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institute on Aging (AG06173, AG015379)
  • MRC
  • ARUK
  • Wellcome Trust
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid hypothesis, amyloid-beta, amyloid-beta 42, amyloid precursor protein, presenilin, gamma-secretase, Down syndrome, APOE ε4, amyloid-beta oligomers, tau hyperphosphorylation, amyloid PET, cerebrospinal fluid biomarkers, anti-amyloid antibodies, solanezumab, crenezumab, aducanumab, amyloid clearance, neurofibrillary tangles, synaptic dysfunction
MeSH terms
Alzheimer Disease, Animals, Brain, Humans, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Rats, Presenilins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The amyloid hypothesis of Alzheimer's disease at 25 years. https://app.cochat.ai/papers/10.15252/emmm.201606210
The paper
Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201606210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.